Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891848251> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2891848251 endingPage "e23506" @default.
- W2891848251 startingPage "e23506" @default.
- W2891848251 abstract "e23506 Background: Osteosarcoma (OS), characterized by the production of osteoid material by malignant osteoblastic cells, is the most common highly malignant primary bone-tumor. Despite its relatively low incidence rate among overall cancers, it remains one of the most harmful primary malignant tumors in childhood and adolescence. It is now evident that serum autoantibodies against tumor-associated antigens (TAAs) could be used as serological cancer biomarkers in types of cancers. Methods: Serological proteome analysis (SERPA) approach was implemented for the identification of TAAs that induce antibody responses in OS. Sera from OS, Osteochondroma (OC) and Normal Human Sera (NHS) were probed by immunoblotting against cellular proteins extracted from U2-OS and Saos-2 cell lines, with OS sera showing stronger immunoreactivity. MALDI-TOF/TOF Mass Spectrometry (MS) analysis of immunoreactive protein spots revealed that several OS sera contained autoantibodies to a number of proteins, particularly to alpha-enolase (ENO1). Results: The immunoseroproteomics profiling led to the identification of 20 potential TAAs of 56 protein spots targeted by serum autoantibodies in OS patients compared with the NHS pool. Especially, ENO1 (11 of 12) had a higher immunoreactive frequencies in sera with OS. Analysis of 172 serum samples from patients with OS, OC and NHS by ELISA showed higher frequency of anti-ENO1 autoantibodies in OS sera compared to others. The results of ROC curves analysis of anti-ENO1 autoantibody indicate it predominately discriminate the OS group from OC as well as can differentiate OC patients from normal individuals. The expression of ENO1 in Osteosarcoma tissues was evaluated by immunohistochemistry in tumor microarray. Conclusions: Taken together, our results suggested that the autoantibody to ENO1 might be considered as a potential serological biomarker for OS. Key words: Osteosarcoma (OS), Tumor-associated antigen (TAA), Serological proteome analysis, ENO1, Immunodiagnosis." @default.
- W2891848251 created "2018-09-27" @default.
- W2891848251 creator A5021825380 @default.
- W2891848251 creator A5023105695 @default.
- W2891848251 creator A5046025033 @default.
- W2891848251 creator A5068727306 @default.
- W2891848251 creator A5079827153 @default.
- W2891848251 creator A5079894628 @default.
- W2891848251 date "2018-05-20" @default.
- W2891848251 modified "2023-09-23" @default.
- W2891848251 title "Detection of autoantibodies against alpha-enolase (ENO1) as potential biomarkers improving immunodiagnosis in human osteosarcoma by serological proteome analysis." @default.
- W2891848251 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.e23506" @default.
- W2891848251 hasPublicationYear "2018" @default.
- W2891848251 type Work @default.
- W2891848251 sameAs 2891848251 @default.
- W2891848251 citedByCount "1" @default.
- W2891848251 countsByYear W28918482512019 @default.
- W2891848251 crossrefType "journal-article" @default.
- W2891848251 hasAuthorship W2891848251A5021825380 @default.
- W2891848251 hasAuthorship W2891848251A5023105695 @default.
- W2891848251 hasAuthorship W2891848251A5046025033 @default.
- W2891848251 hasAuthorship W2891848251A5068727306 @default.
- W2891848251 hasAuthorship W2891848251A5079827153 @default.
- W2891848251 hasAuthorship W2891848251A5079894628 @default.
- W2891848251 hasConcept C104397665 @default.
- W2891848251 hasConcept C142724271 @default.
- W2891848251 hasConcept C159654299 @default.
- W2891848251 hasConcept C163764329 @default.
- W2891848251 hasConcept C203014093 @default.
- W2891848251 hasConcept C2777760704 @default.
- W2891848251 hasConcept C45189115 @default.
- W2891848251 hasConcept C502942594 @default.
- W2891848251 hasConcept C60644358 @default.
- W2891848251 hasConcept C71924100 @default.
- W2891848251 hasConcept C86803240 @default.
- W2891848251 hasConceptScore W2891848251C104397665 @default.
- W2891848251 hasConceptScore W2891848251C142724271 @default.
- W2891848251 hasConceptScore W2891848251C159654299 @default.
- W2891848251 hasConceptScore W2891848251C163764329 @default.
- W2891848251 hasConceptScore W2891848251C203014093 @default.
- W2891848251 hasConceptScore W2891848251C2777760704 @default.
- W2891848251 hasConceptScore W2891848251C45189115 @default.
- W2891848251 hasConceptScore W2891848251C502942594 @default.
- W2891848251 hasConceptScore W2891848251C60644358 @default.
- W2891848251 hasConceptScore W2891848251C71924100 @default.
- W2891848251 hasConceptScore W2891848251C86803240 @default.
- W2891848251 hasIssue "15_suppl" @default.
- W2891848251 hasLocation W28918482511 @default.
- W2891848251 hasOpenAccess W2891848251 @default.
- W2891848251 hasPrimaryLocation W28918482511 @default.
- W2891848251 hasRelatedWork W2027411698 @default.
- W2891848251 hasRelatedWork W2101875571 @default.
- W2891848251 hasRelatedWork W2134281733 @default.
- W2891848251 hasRelatedWork W2138718875 @default.
- W2891848251 hasRelatedWork W2186438635 @default.
- W2891848251 hasRelatedWork W2415121269 @default.
- W2891848251 hasRelatedWork W2425255793 @default.
- W2891848251 hasRelatedWork W2919504568 @default.
- W2891848251 hasRelatedWork W3122727118 @default.
- W2891848251 hasRelatedWork W2484185186 @default.
- W2891848251 hasVolume "36" @default.
- W2891848251 isParatext "false" @default.
- W2891848251 isRetracted "false" @default.
- W2891848251 magId "2891848251" @default.
- W2891848251 workType "article" @default.